Treatment of acute coronary syndrome with glp-1
CA 2407784 C · Owner: Astrazeneca Pharmaceuticals Lp · Inventors: Coolidge, Thomas R.; Ehlers, Mario
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The invention relates to methods for treating a patient suffering from acute coronary syndrome, but who is not suffering from a Q-wave myocardial infarction, comprising administration of a therapeutically effective amount of a GLP-1 molecule. The GLP-1 can be self-administered and can be administered , in one or more doses as needed, on an intermittent or continuous basis to , optimize metabolism in cardiac tissue and to prevent cardiac damage associated with ischemia.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed May 18, 2001 and granted August 26, 2014. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended May 18, 2021.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by May 18, 2023.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.